Novo Nordisk A/S: Transaction in Own Shares

BAGSVÆRD, DENMARK--(Marketwire - April 06, 2009) - On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.

Since the announcement as of 30 March 2009, the following transactions have been made under the programme:

                  Number of    Average      Transaction
                   shares   purchase price  value, DKK
Accumulated, last
announcement      3,317,500                  944,916,745
30 March 2009        75,000         278.10    20,857,500
31 March 2009       150,000         272.99    40,948,650
1 April 2009         60,000         277.50    16,650,000
2 April 2009         70,000         276.54    19,357,800
3 April 2009        159,541         246.10    39,263,040
Accumulated under
the programme     3,832,041                1,081,993,735

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 170 B shares in the period from 30 March 2009 to 3 April 2009. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 28,684,423 treasury shares, corresponding to 4.5% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Company Announcement no 21 / 2009

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Copyright © Hugin AS 2009. All rights reserved.